So low ... so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors

被引：35
|
作者：
Gencer, Baris [1 ]
Mach, Francois [1 ]
机构：
[1] Geneva Univ Hosp, Dept Specialties Med, Cardiol Div, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷 / 05期
基金：
瑞士国家科学基金会;
关键词：
COGNITIVE FUNCTION; FOURIER TRIAL; OLDER-ADULTS; CHOLESTEROL; EFFICACY; SAFETY; METAANALYSIS; EVOLOCUMAB; STATINS; DISEASE;
D O I：
10.1093/eurheartj/ehx742
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: meta-analysis of individual patient data'+, by P.D. Harvey et al., on page 374.
引用
收藏
页码：382 / 384
页数：3
相关论文
共 50 条
  • [1] PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet
    Santos, Raul D.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 377 - 379
  • [2] PCSK9 vaccine: so near, yet so far!
    Sahebkar, Amirhossein
    Momtazi-Borojeni, Amir Abbas
    Banach, Maciej
    EUROPEAN HEART JOURNAL, 2021, 42 (39) : 4007 - 4010
  • [3] So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients
    McNutt, Markey C.
    Ahmad, Zahid
    CIRCULATION-CARDIOVASCULAR GENETICS, 2015, 8 (06) : 749 - 751
  • [4] Lowering LDL-C with alirocumab, an investigational PCSK9 inhibitor
    Edelberg, Jay
    CLINICAL LIPIDOLOGY, 2014, 9 (06) : 603 - 606
  • [5] PCSK9 inhibitors for LDL lowering
    Walsh, Lames P.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2015, 25 (07) : 575 - 577
  • [6] Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering
    Rodriguez, Fatima
    Harrington, Robert A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (19): : 1967 - 1968
  • [7] Statins and LDL-C in Secondary Prevention-So Much Progress, So Far to Go
    Banach, Maciej
    Penson, Peter E.
    JAMA NETWORK OPEN, 2020, 3 (11)
  • [8] What have we learned so far from the biology of PCSK9?
    Seidah, Nabil G.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1343 - 1344
  • [9] Sweetless'n low LDL-C targets for PCSK9 treatment
    Gencer, Baris
    Mach, Francois
    EUROPEAN HEART JOURNAL, 2015, 36 (19) : 1146 - 1148
  • [10] Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C
    Kelsey, Michelle D.
    Newby, L. Kristin
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (08) : JC86 - JC86
12345